MaxCyte Share News (MXCT)

MaxCyte Information

Buy MXCT Shares
Add MXCT to Watchlist
Add MXCT to Alert

Share Price Information for MaxCyte (MXCT)

Share Price is delayed by 15 minutes

Get Live Data

Share Price: 322.00

Bid: 314.00

Ask: 330.00

Change: -6.00 (-1.83%)

Spread: 16.00 (5.096%)

Open: 328.00

High: 328.00

Low: 322.00

Prev. Close: 328.00

Last checked at -

IN BRIEF: MaxCyte Signs APN401 Licensing Deal With Apeiron Biologics

Wed, 08th Jul 2020 15:51

MaxCyte Inc - cell and gene therapies - Signs clinical and commercial licensing agreement with Apeiron Biologics AG. Apeiron to obtain non-exclusive clinical and commercial rights to use MaxCyte's Flow Electroporation technology and ExPert platform for advancing APN401, a cell-therapy in development for solid tumours. MaxCyte will receive undisclosed development and approval milestones, with sales-based payments and licensing fees.

Current stock price: 208.80 pence

Year-to-date change: up 69%

By Dayo Laniyan; dayolaniyan@alliancenews.com

More News

25 Apr 2018 12:17

MaxCyte Hires Claudio Dansky Ullmann As New Chief Medical Officer

LONDON (Alliance News) - Cell-based medicine and life science company MaxCyte Inc on Wednesday announced the appointment of Claudio Dansky Ullmann as its new chief medical officer.Dansky be

4 Apr 2018 12:10

MaxCyte Revenue Up But Loss Widens On Investments In CARMA Platform

LONDON (Alliance News) - MaxCyte Inc on Wednesday reported revenue growth in its recently finished financial year, but its loss significantly widened on spending on its cell a

24 Jan 2017 08:15

MaxCyte Expects 2016 Pretax Loss To Be Better Than Market Expectations

16 Jan 2017 12:41

Unicorn AIM Net Asset Value Stable In Final Quarter Of 2016

12 Jul 2016 08:16

MaxCyte Trading In Line With Revenue Higher And Pipeline Progressing

10 May 2016 08:50

MaxCyte Loss Narrows In 2015 And Set For Further Progress In 2016

29 Mar 2016 08:18

Latest Share Chat

MaxCyte Share News (MXCT)

Share Price Information for MaxCyte (MXCT)

IN BRIEF: MaxCyte Signs APN401 Licensing Deal With Apeiron Biologics

MaxCyte Hires Claudio Dansky Ullmann As New Chief Medical Officer

MaxCyte Revenue Up But Loss Widens On Investments In CARMA Platform

MaxCyte Expects 2016 Pretax Loss To Be Better Than Market Expectations

Unicorn AIM Net Asset Value Stable In Final Quarter Of 2016

MaxCyte Trading In Line With Revenue Higher And Pipeline Progressing

MaxCyte Loss Narrows In 2015 And Set For Further Progress In 2016

Harwood And MaxCyte Up On AIM Debuts; Forterra To Float (ALLIPO)

Latest Share Chat

MaxCyte Share News (MXCT)

Share Price Information for MaxCyte (MXCT)

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

IN BRIEF: MaxCyte Signs APN401 Licensing Deal With Apeiron Biologics

MaxCyte Hires Claudio Dansky Ullmann As New Chief Medical Officer

MaxCyte Revenue Up But Loss Widens On Investments In CARMA Platform

MaxCyte Expects 2016 Pretax Loss To Be Better Than Market Expectations

Unicorn AIM Net Asset Value Stable In Final Quarter Of 2016

MaxCyte Trading In Line With Revenue Higher And Pipeline Progressing

MaxCyte Loss Narrows In 2015 And Set For Further Progress In 2016

Harwood And MaxCyte Up On AIM Debuts; Forterra To Float (ALLIPO)

Login to your account

Quickpicks are a member only feature

Login to your account